Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
260M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
3.13M
-
Shares change
-
-213K
-
Total reported value, excl. options
-
$9.69M
-
Value change
-
-$924K
-
Number of buys
-
7
-
Number of sells
-
-8
-
Price
-
$3.10
Significant Holders of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) as of Q2 2024
25 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.13M shares
of 260M outstanding shares and own 1.2% of the company stock.
Largest 10 shareholders include BVF INC/IL (918K shares), RTW INVESTMENTS, LP (767K shares), MARSHALL WACE, LLP (459K shares), Sessa Capital IM, L.P. (458K shares), VANGUARD GROUP INC (276K shares), GEODE CAPITAL MANAGEMENT, LLC (59.4K shares), MILLENNIUM MANAGEMENT LLC (52.8K shares), Pathstone Holdings, LLC (50.7K shares), FIRST MANHATTAN CO. LLC. (24.6K shares), and First PREMIER Bank (19.4K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.